ARTICLE | Clinical News
Tavocept: Phase II data
July 21, 2008 7:00 AM UTC
In a U.S. Phase II trial in 151 patients with advanced NSCLC, Tavocept plus Taxotere docetaxel and cisplatin missed the co-primary endpoint of a significantly improved objective response rate vs. doc...